ArticleBMC cancer2026
MMP1 is a promising prognostic, therapeutic and immunological biomarker for pancreatic cancer: evidence from bioinformatics analysis and biological experiments.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPancreatic cancer remains one of the most lethal malignancies worldwide, underscoring the urgent need for reliable biomarkers to predict prognosis and guide therapy. This study aimed to identify and characterize such biomarkers using an integrated bioinformatics and experimental approach.
methodsThe GEO database was used to screen genes differentially expressed in pancreatic cancer. Next, the DAVID database was used for GO functional enrichment and KEGG pathway analyses. STRING database and Cytoscape software were utilized to generate PPI networks and identify key genes. The prognostic value was then evaluated by utilizing the GEPIA database and Cox regression analysis. The relationship between key genes and clinicopathological parameters was analyzed using the UALCAN database. The TISCH2, TIMER, and TISDB databases were used for immune infiltration analysis. The functional role of the key gene was ultimately confirmed through in vitro experiments.
resultsThrough multiple rounds of strict screening, 10 key genes were obtained. After further verification, it was determined that MMP1 was significantly upregulated in pancreatic cancer tissue and correlated with poor prognosis in patients. Immunological analysis revealed correlations between MMP1 expression and the infiltration of specific immune cells (B cells, M1 macrophages, neutrophils, and monocytes) as well as the expression of immune checkpoint genes (VTCN1, LGALS9, TGFBR1, and IL10RB). In vitro functional assays confirmed that MMP1 knockdown in pancreatic cancer cells suppressed proliferation, migration, and invasion, while promoting apoptosis. Furthermore, a co-culture model demonstrated that MMP1 facilitated the recruitment of M1-polarized macrophages.
conclusionMMP1 is an independent prognostic biomarker that drives pancreatic cancer progression through direct oncogenic effects and modulation of the tumor immune microenvironment. Thus, it emerges as an attractive, multifunctional therapeutic target, which calls for future research to confirm its translational potential and delineate the underlying molecular pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.